A biosimilar is the follow-on drug to a biological.

Biosimilars have been available in Switzerland since 2009. With the patent expiry of major biologicals, the range of products available has increased significantly in recent years.

Biosimilars are approved by the Swiss regulatory and supervisory authority (Swissmedic). It confirms that biosimilars are comparable to the reference drug in terms of efficacy, safety and quality.

You can think of therapy with a biosimilar as continuing your current therapy. This is because the treatment is conducted with the same active ingredient.